High-density Mapping Guided Pulmonary Vein Isolation for Treatment of Atrial Fibrillation - Two-year clinical outcome of a single center experience

• Published in: Scientific reports Vol. 9; no. 1; pp. 8830 - 8
• Main Authors: Siebermair, J., Neumann, B., Risch, F., Riesinger, L., Vonderlin, N., Koehler, M., Lackermaier, K., Fichtner, S., Rizas, K., Sattler, S. M., Sinner, M. F., Kääb, S., Estner, H. L., Wakili, R.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20-06-2019; Nature Publishing Group
• Subjects: 692/4019; 692/699/75/29/1309; Aged; Arrhythmia; Atrial Fibrillation - therapy; Cardiac arrhythmia; Catheter Ablation; Clinical outcomes; Clinical trials; Epicardial Mapping - methods; Female; Fibrillation; Fluoroscopy; Fluoroscopy - methods; Humanities and Social Sciences; Humans; Male; Mapping; Middle Aged; multidisciplinary; Patients; Pulmonary Veins - physiopathology; Pulmonary Veins - surgery; Radiation Exposure; Recurrence; Retrospective Studies; Science; Science (multidisciplinary); Treatment Outcome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-45115-0

Pulmonary vein isolation (PVI) as interventional treatment for atrial fibrillation (AF) aims to eliminate arrhythmogenic triggers from the PVs. Improved signal detection facilitating a more robust electrical isolation might be associated with a better outcome. This retrospective cohort study compared PVI procedures using a novel high-density mapping system (HDM) with improved signal detection vs. age- and sex-matched PVIs using a conventional 3D mapping system (COM). Endpoints comprised freedom from AF and procedural parameters. In total, 108 patients (mean age 63.9 ± 11.2 years, 56.5% male, 50.9% paroxysmal AF) were included (n = 54 patients/group). Our analysis revealed that HDM was not superior regarding freedom from AF (mean follow-up of 494.7 ± 26.2 days), with one- and two-year AF recurrence rates of 38.9%/46.5% (HDM) and 38.9%/42.2% (COM), respectively. HDM was associated with reduction in fluoroscopy times (18.8 ± 10.6 vs. 29.8 ± 13.4 min; p < 0.01) and total radiation dose (866.0 ± 1003.3 vs. 1731.2 ± 1978.4 cGy; p < 0.01) compared to the COM group. HDM was equivalent but not superior to COM with respect to clinical outcome after PVI and resulted in reduced fluoroscopy time and radiation exposure. These results suggest that HDM-guided PVI is effective and safe for AF ablation. Potential benefits in comparison to conventional mapping systems, e.g. arrhythmia recurrence rates, have to be addressed in randomized trials.